CD274 and esophageal squamous cell carcinoma: Random-effects meta-analysis demonstrated no statistically significant study-level differences in response to immunotherapy between the sexes in the overall population (OS, I<sup>2</sup> = 14%; P = 0.94; PFS, I<sup>2</sup> = 18%; P = 0.95) as well as in the PD-L1-positive subgroup (PFS, I<sup>2</sup> = 0%; P = 0.24).<h4>Conclusion</h4>First-line immunotherapy plus chemotherapy can improve OS and PFS in advanced ESCC for both men and women.